Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on March 3, 2022. The filing discloses the entry into a Material Definitive Agreement with Haisco Pharmaceutical Group Co., Ltd., a pharmaceutical company based in China.
Key Financial Metrics and Transaction Terms
The filing details a License, Development and Supply Agreement regarding the Company's product Exservan (riluzole oral film) for the treatment of amyotrophic lateral sclerosis (ALS) in China. Key financial terms include:
- Upfront Payment: $7 million in cash.
- Milestone Payments: Regulatory milestone payments (specific amounts not disclosed).
- Royalties: Double-digit royalties on net sales of Exservan in China.
- Manufacturing Revenue: The Company will earn revenue as the exclusive sole manufacturer and supplier.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the Company.
Material Changes and Strategic Developments
The primary material change is the strategic partnership with Haisco to develop and commercialize Exservan in China. Under the agreement:
- Haisco will lead regulatory and commercialization activities in China.
- Aquestive retains exclusive manufacturing and supply rights.
- The agreement term expires on the 10-year anniversary of the first commercial sale in China, subject to renewal.
- Intellectual property developed by a single party is owned by that party, while jointly developed IP is jointly owned.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The agreement positions Aquestive to monetize its intellectual property in the Chinese market through upfront capital, future royalties, and manufacturing fees.
Risks and Contingencies:
- Termination for Cause: Either party may terminate the agreement with 90 days' written notice if marketing authorization in China is not granted within three years of the effective date.
- Regulatory Risk: Success depends on Haisco obtaining marketing authorization in China.
- Contractual Standards: Representations and warranties are subject to contract standards of materiality that may differ from securities laws.
Investor Verification Checklist
- Verify the receipt of the $7 million upfront cash payment in the Company's next quarterly financial report (Form 10-Q).
- Confirm the specific dollar amounts of the regulatory milestone payments, which are not detailed in this filing.
- Monitor the timeline for marketing authorization in China to assess the risk of termination after the three-year mark.
- Review the full text of the License and Supply Agreement filed as an exhibit to the Form 10-Q for the period ended March 31, 2022.